Clinical Trials : Angelman Syndrome

Completed

Study Name: Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances
Condition: Sleep Problems
Date: 2013-07-16
Interventions:

Drug: Circadin 2 mg First arm

Completed

Study Name: Genomic Imprinting and Assisted Reproductive Technologies
Condition:

Natural Pregnancy
Pregnancy, Ovarian

Date: 2008-10-15

Withdrawn

Study Name: An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder
Condition: Autism Spectrum Disorder
Date: 2014-08-21
Interventions: Drug: EPI-743 Other Name: Vincerinone TM

Active, not recruiting

Study Name: Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
Condition: Sleep Disorders
Date: 2013-07-11
Interventions:

Drug: Circadin 2/5/10 mg Activ

COMPLETED

Study Name: Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome
Condition: Angelman Syndrome
Date: 2025-01-14
Interventions: The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device.In this study, the testing involved with t

RECRUITING

Study Name: Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
Condition: Angelman Syndrome
Date: 2025-01-14
Interventions: Participants aged 15-17 years or above receiving the adult 60 mg of alogabat dose.I

COMPLETED

Study Name: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
Condition: Angelman Syndrome
Date: 2025-01-14
Interventions: NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.

Search for Clinical Trial Results

Angelman Syndrome - 7 Studies Found

Status	Study
Completed	Study Name: Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances Condition: Sleep Problems Date: 2013-07-16 Interventions: Drug: Circadin 2 mg First arm
Completed	Study Name: Genomic Imprinting and Assisted Reproductive Technologies Condition: Natural Pregnancy Pregnancy, Ovarian Date: 2008-10-15
Withdrawn	Study Name: An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder Condition: Autism Spectrum Disorder Date: 2014-08-21 Interventions: Drug: EPI-743 Other Name: Vincerinone TM
Active, not recruiting	Study Name: Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities Condition: Sleep Disorders Date: 2013-07-11 Interventions: Drug: Circadin 2/5/10 mg Activ
COMPLETED	Study Name: Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome Condition: Angelman Syndrome Date: 2025-01-14 Interventions: The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device.In this study, the testing involved with t
RECRUITING	Study Name: Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. Condition: Angelman Syndrome Date: 2025-01-14 Interventions: Participants aged 15-17 years or above receiving the adult 60 mg of alogabat dose.I
COMPLETED	Study Name: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome Condition: Angelman Syndrome Date: 2025-01-14 Interventions: NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.